Quoin Pharmaceuticals (QNRX) Q3 2026 earnings review
Quoin raises cash and posts trial wins, but shares double
Quoin Pharmaceuticals, a rare-disease skin drug developer, refilled its bank account and posted positive early trial results at the cost of heavy shareholder dilution. An August private stock placement brought in $31 million upfront, lifting cash and investments to $33 million while more than doubling the traded share count. In its main Netherton Syndrome trial, four of the first six patients met the primary skin-clearing goal after 12 weeks, and chief executive Dr. Michael Myers set the full 20-patient readout for the second quarter of 2027.
| Cash and investments | $33.2M up from $10.8M last quarter |
|---|---|
| Quarterly net loss | $4.9M +23% from a year ago |
| Traded ADS share count | 4.80M +139% from last quarter |
| Cash runway outlook | Raised into 2028 (was into 2027) |
⚖️ Verdict: 🟢 Bullish
The story got better because the August financing removed the risk of running out of cash before the main trial finishes, extending the company's runway into 2028. Interim trial data also showed for the first time that QRX003 clears skin in a controlled study, though the full readout is now six months later than planned at the start of the year.
The question now is whether Quoin can finish recruiting all 20 Netherton Syndrome patients by December and repeat its 67% response rate without needing another dilutive stock sale. If the full 20-patient trial matches the six-patient interim result, Quoin can file for US approval and qualify for a transferable priority review voucher; if enrollment slips or efficacy fades, warrant holders will stay on the sidelines. The second-quarter 2027 topline readout will settle it.
🐂 Bull Case
August Financing Extends Cash Runway Into 2028
Quoin entered the third quarter with $10.8 million in cash and investments, barely two quarters of spending. In August, the rare-disease drug developer raised $30.8 million upfront in a private stock placement with healthcare investors, lifting its cash and investments to $33.2 million at September 30.
Chief executive Dr. Michael Myers said the deal provides "funding to fully complete the development of QRX003 for Netherton Syndrome, whilst enabling us to selectively invest in the advancement of our pipeline products". By our math, $33.2 million covers nearly seven quarters at the third-quarter operating expense rate of $4.9 million, which supports "the Company’s belief that its current cash position will fund operations into 2028".
What to watch: cash and investments in the fourth-quarter report. Staying above $27 million at year-end would confirm that starting the second clinical trial is not accelerating cash burn beyond the new two-year plan.
Lead Lotion Shows Positive Interim Trial Results
Quoin is testing QRX003, a topical lotion for Netherton Syndrome, a severe genetic skin disorder with no approved cure. On August 28, the drugmaker reported interim data from the first six patients to finish 12 weeks of treatment in its late-stage trial, which Myers called the "first ever overall positive data set published for this disease".
- Primary goal (skin clearing score improvement): 4 of 6 patients (66.7%), statistically significant (p=0.0087 vs 0.0215 target)
- Severe itch reduction: 3 of 3 patients improved by at least 3 grades
- Compassionate use case report: 1 child cleared from severe to clear skin over 21 months
- Safety: zero treatment-related serious side effects reported
The readout matters because statistical significance on a strict threshold in just six patients shows a clear treatment effect. What to watch: full topline results from all 20 patients in the second quarter of 2027, where repeating this response rate would support an approval filing.
Peeling Skin Program Clears Regulatory Hurdles
Quoin is expanding QRX003 into a second rare disorder, Peeling Skin Syndrome, where the outer layer of skin constantly sheds. In July, US regulators cleared Quoin's application to begin human trials, and the company won US Fast Track, US Rare Pediatric Disease, and European Orphan Drug designations over the following तीन months.
Across both skin diseases, QRX003 now holds eight regulatory designations in the US, Europe and Japan. The European status guarantees 10 years of market protection if approved, and the US pediatric tag makes Quoin eligible for a priority review voucher that drugmakers can sell for cash.
What to watch: the start of the 12-patient Peeling Skin Syndrome trial before the end of 2026. Dosing the first patient on time would prove Quoin can run two late-stage rare-disease studies at once.
🐻 Bear Case
Share Count More Than Doubled to Fund Operations
"The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth," Myers said. While the August placement fixed the cash shortage, existing shareholders paid a steep price in ownership dilution as the number of American Depositary Shares (ADSs, the traded stock units representing 35 ordinary shares) more than doubled in a single quarter.
Issued ADSs jumped 139% from June to 4.80 million at September 30, and are up more than eightfold from 588,166 a year ago. The August deal also attached warrants that could bring in $19.2 million if exercised, adding to the 9.71 million warrant ADSs already sitting overhead from earlier financings.
Because Quoin has no revenue, every new share permanently splits future drug profits and any priority review voucher proceeds across a much larger base. What to watch: the warrant table in the third-quarter Form 10-Q filing, which will disclose the exact count and exercise prices of the newly issued warrants.
Main Trial Data Pushed to Second Quarter 2027
Earlier this year, Quoin told investors to expect topline data from its pivotal Netherton Syndrome program in the second half of 2026, before dropping the target date in the second quarter. On Thursday, Myers set a new schedule: "We expect to complete recruitment in our Netherton Syndrome study by year end and report topline data in the second quarter of 2027."
Having a concrete date again is better than silence, and six patients had already completed 12 weeks of dosing by late August. However, the full readout is now roughly six months later than the company's start-of-year plan, and the target to file an application for its second drug platform, QRX009 (a topical rapamycin lotion), also slipped from the third quarter to year-end.
What to watch: confirmation in early 2027 that all 20 Netherton Syndrome patients enrolled by December 31. Any enrollment delay past year-end would push the second-quarter 2027 readout and potential approval filing back again.
Risks this quarter didn't answer
Three standing operational and governance concerns remained open or untestable in the third-quarter earnings release.
- Officer debt repayments: Quoin paid another $150,000 toward pre-merger officer debt in Q3, cutting the balance to $1.87 million, and continues paying cash to founders before generating revenue.
- Pipeline spending discipline: starting the Peeling Skin Syndrome trial and QRX009 studies will test whether quarterly spending stays near $5 million; Q4 R&D expenses will give the first reading.
- Trial design and supplier reliance: the release did not state whether the FDA signed formal minutes for the single-trial design or whether single-source contractor risks changed; the Form 10-Q filing will update both.
💲 Other KPIs
Research and development spending — the cost of running clinical trials and manufacturing test batches — rose 16.4% from a year ago, but dropped 26.8% from $3.63 million in the second quarter. For the first nine months of 2026, research spending reached $9.72 million, up 44.9% from the prior year as late-stage trials progressed.
General and administrative spending — executive pay, legal bills, and disease awareness campaigns — climbed 30.4% from a year ago and 22.8% from the second quarter. It was the fastest quarterly increase in over a year, offsetting part of the drop in research costs and keeping total operating expenses at $4.92 million.
Accounts payable — unpaid bills owed to clinical trial contractors and vendors — fell by nearly half from $3.11 million at June 30. Before the August financing closed, Quoin conserved cash by letting vendor bills build up; after raising $30.8 million, the company paid down $1.53 million of payables and cleared $1.15 million in accrued financing costs.
🔮 Guidance
Raised. Quoin now expects its $33.2 million in cash and marketable securities to fund operations into 2028, adding a full year to the prior target of into 2027. By our math, the balance covers 6.7 quarters at the third-quarter operating expense rate of $4.92 million, even after paying down $2.68 million in overdue bills and financing accruals during the quarter.
Cut. Management kept the year-end 2026 target to finish recruiting all 20 patients in its late-stage Netherton Syndrome trial, but pushed the topline data readout to the second quarter of 2027. In the first quarter, the plan called for topline results in the second half of 2026, before the date was left out of the second-quarter update.
Unchanged. Quoin still plans to start its Phase 2/3 trial in Peeling Skin Syndrome before the end of 2026. Following US regulatory clearance in July, the trial will enroll up to 12 adult and pediatric patients across the US and Europe.
Unchanged from Q2. The company plans to submit a US regulatory application to begin human testing of its QRX009 topical rapamycin platform before the end of 2026, and start clinical trials in early 2027. The application was originally planned for the third quarter of 2026.
❓ Key Questions
How many Netherton patients are enrolled right now?
Six patients had completed 12 weeks of treatment by August 28, and Quoin plans to finish recruiting all 20 patients by December 31. Knowing how many patients are currently dosed would show whether the second-quarter 2027 readout date is safe.
What are the exercise prices on the August warrants?
Quoin could receive up to $19.2 million from warrants issued in the August private placement, but earlier warrants at $11.02 per ADS sit far out of the money. The exercise price determines whether this cash can arrive after the 2027 trial readout.
Why did general and administrative costs jump 23% this quarter?
Administrative spending rose to $2.27 million from $1.85 million in the second quarter while research spending fell. Investors need to know if this reflects one-off financing fees or a permanent step-up in overhead from the new European and Japanese operations.
Has the FDA formally approved the single-trial no-placebo design?
Following a March meeting, the FDA indicated a single Phase 3 study without an upfront placebo group might suffice for approval. Quoin has not confirmed whether written regulatory agreement is now locked in for a 2027 approval application.